Roberto Mallone

Summary

Country: France

Publications

  1. ncbi Immunology of Diabetes Society T-Cell Workshop: HLA class I tetramer-directed epitope validation initiative T-Cell Workshop Report-HLA Class I Tetramer Validation Initiative
    R Mallone
    INSERM U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, and Paris Descartes University, Paris, France
    Diabetes Metab Res Rev 27:720-6. 2011
  2. ncbi Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society
    R Mallone
    INSERM U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, 82 avenue Denfert Rochereau, Paris Cedex 14, France
    Clin Exp Immunol 163:33-49. 2011
  3. ncbi Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice
    Emmanuelle Enée
    Institut National de la Sante et de la Recherche Medicale, Unité 580, Paris, France
    J Immunol 180:5430-8. 2008
  4. ncbi HLA-B7-restricted islet epitopes are differentially recognized in type 1 diabetic children and adults and form weak peptide-HLA complexes
    Matthieu Scotto
    INSERM, U986, DeAR Lab Avenir, Cochin Saint Vincent de Paul Hospital, Paris, France
    Diabetes 61:2546-55. 2012
  5. ncbi Beyond the hormone: insulin as an autoimmune target in type 1 diabetes
    Vedran Brezar
    Institut National de la Sante et de la Recherche Medicale, Unité 986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, and Paris Descartes University, 82 avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Endocr Rev 32:623-69. 2011
  6. ncbi Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms
    Georgia Afonso
    INSERM, U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, 82 avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    J Immunol Methods 359:28-36. 2010
  7. ncbi acDCs enhance human antigen-specific T-cell responses
    Emanuela Martinuzzi
    INSERM U986, Diabetes and Autoimmunity Research Laboratory, Paris, France
    Blood 118:2128-37. 2011
  8. ncbi T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives
    Roberto Mallone
    INSERM, U986, Hopital St Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, France
    Clin Dev Immunol 2011:513210. 2011
  9. ncbi Insulin and type 1 diabetes: immune connections
    Sloboda Culina
    INSERM, U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, 82 avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Eur J Endocrinol 168:R19-31. 2013
  10. ncbi T cells recognizing a peptide contaminant undetectable by mass spectrometry
    Vedran Brezar
    INSERM, U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, Paris, France
    PLoS ONE 6:e28866. 2011

Collaborators

Detail Information

Publications17

  1. ncbi Immunology of Diabetes Society T-Cell Workshop: HLA class I tetramer-directed epitope validation initiative T-Cell Workshop Report-HLA Class I Tetramer Validation Initiative
    R Mallone
    INSERM U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, and Paris Descartes University, Paris, France
    Diabetes Metab Res Rev 27:720-6. 2011
    ..Identification of T-cell reactivity to β-cell antigen epitopes is an important goal for studying pathogenesis and for designing and monitoring of immunotherapeutic interventions in type 1 diabetes (T1D)...
  2. ncbi Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society
    R Mallone
    INSERM U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, 82 avenue Denfert Rochereau, Paris Cedex 14, France
    Clin Exp Immunol 163:33-49. 2011
    ..These recommendations may be relevant not only for the analysis of T cell responses in autoimmune disease, but also in cancer and infectious disease, particularly in the context of clinical trials...
  3. ncbi Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice
    Emmanuelle Enée
    Institut National de la Sante et de la Recherche Medicale, Unité 580, Paris, France
    J Immunol 180:5430-8. 2008
    ....
  4. ncbi HLA-B7-restricted islet epitopes are differentially recognized in type 1 diabetic children and adults and form weak peptide-HLA complexes
    Matthieu Scotto
    INSERM, U986, DeAR Lab Avenir, Cochin Saint Vincent de Paul Hospital, Paris, France
    Diabetes 61:2546-55. 2012
    ..These features may explain the T1D-protective effect of HLA-B7. The novel epitopes identified should find valuable applications for immune staging of HLA-B7(+) individuals...
  5. ncbi Beyond the hormone: insulin as an autoimmune target in type 1 diabetes
    Vedran Brezar
    Institut National de la Sante et de la Recherche Medicale, Unité 986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, and Paris Descartes University, 82 avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Endocr Rev 32:623-69. 2011
    ..We will argue about possible reasons why insulin remains the mainstay of metabolic control in type 1 diabetes but has so far failed to prevent or halt β-cell autoimmunity as an immune modulatory reagent...
  6. ncbi Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms
    Georgia Afonso
    INSERM, U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, 82 avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    J Immunol Methods 359:28-36. 2010
    ..However, washes with > 10% human serum decreased multimer counts, with no additional improvement in PBMC yields. These findings may be relevant for optimizing and harmonizing PBMC processing procedures for T-cell assays...
  7. ncbi acDCs enhance human antigen-specific T-cell responses
    Emanuela Martinuzzi
    INSERM U986, Diabetes and Autoimmunity Research Laboratory, Paris, France
    Blood 118:2128-37. 2011
    ....
  8. ncbi T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives
    Roberto Mallone
    INSERM, U986, Hopital St Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, France
    Clin Dev Immunol 2011:513210. 2011
    ..This may prove instrumental in the discovery of immune correlates of efficacy in clinical trials...
  9. ncbi Insulin and type 1 diabetes: immune connections
    Sloboda Culina
    INSERM, U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, 82 avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Eur J Endocrinol 168:R19-31. 2013
    ....
  10. ncbi T cells recognizing a peptide contaminant undetectable by mass spectrometry
    Vedran Brezar
    INSERM, U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, Paris, France
    PLoS ONE 6:e28866. 2011
    ..If left undetected, minute impurities in synthetic peptide preparations may thus give spurious results...
  11. ncbi Short-term subcutaneous insulin treatment delays but does not prevent diabetes in NOD mice
    Vedran Brezar
    INSERM, U986, DeAR Lab Avenir, Cochin Saint Vincent de Paul Hospital, Paris, France Université Paris Descartes, Sorbonne Paris Cité, Paris, France
    Eur J Immunol 42:1553-61. 2012
    ..These findings have important implications for designing insulin-based prevention trials...
  12. ncbi Measurement of CD8 T cell responses in human type 1 diabetes
    Emanuela Martinuzzi
    INSERM, U561, Saint Vincent de Paul Hospital, 75014 Paris, France
    Ann N Y Acad Sci 1150:61-7. 2008
    ..Second, appropriate readouts and measurement techniques need to be selected. This review summarizes recent advances on both of these battlefronts, and discusses the potential clinical applications of T cell assays...
  13. ncbi The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment
    Emanuela Martinuzzi
    INSERM U580, Paris, France
    Diabetes 57:1312-20. 2008
    ..The predominant T-cell specificities change over time, but whether similar shifts also occur after clinical diagnosis and insulin treatment in type 1 diabetic patients is unknown...
  14. ncbi Single insulin-specific CD8+ T cells show characteristic gene expression profiles in human type 1 diabetes
    Sandrine Luce
    INSERM, U986, Paris, France
    Diabetes 60:3289-99. 2011
    ....
  15. ncbi Pathogenic and regulatory T cells in type 1 diabetes: losing self-control, restoring it, and how to take the temperature
    Slobodan Culina
    INSERM U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, 75674, Paris, Cedex 14, France
    Curr Diab Rep 11:426-33. 2011
    ..Continuous development of T-cell assays exploring both pathogenic and regulatory players will be critical to "take the temperature" of undergoing disease progression and reversal...
  16. ncbi Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection
    Emanuela Martinuzzi
    INSERM, U580, Necker Hospital, Paris, France
    J Immunol Methods 333:61-70. 2008
    ..Implementation of this ELISpot procedure should expedite development of "immune staging" protocols for autoimmune as well as tumor and infectious diseases...
  17. ncbi Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?
    Slobodan Culina
    INSERM, U986, DeAR Lab Avenir, Saint Vincent de Paul Hospital, 82 avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Clin Dev Immunol 2011:286248. 2011
    ..T1D staging through immune surrogate markers before and after treatment will be key in understanding therapeutic actions and to finally turn ordinary blanks into magic bullets...